gdc
FDA Approvals, News & UpdatesGastric Cancer

Trazimera a New Biosimilar for HER2-Positive Metastatic Gastric or Gastroesophageal Junction Cancer, or Breast Cancer

April 2019 Vol 5 No 2

In March 2019, the FDA approved Trazimera (trastuzumab-qyyp; from Pfizer) as the fourth biosimilar to Herceptin (trastuzumab; from Genentech) for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma or HER2-positive breast cancer. This approval was based on several studies confirming that Trazimera is biosimilar to the original drug, Herceptin.

Biosimilars are drugs that contain the same components of an original (brand-name) drug, such as Herceptin, which was previously approved by the FDA. Biosimilars offer the same treatment benefit, but at a reduced cost, usually about 15% to 30% lower than the cost of the original drug.

Earlier, in January 2019, the FDA approved the third biosimilar to Herceptin, Ontruzant (trastuzumab-dttb; from Merck), also for patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma or HER2-positive breast cancer or HER2-overexpressing metastatic gastric or gastroesophageal junction adeno­carcinoma.

Recommended For You
Gastric Cancer
Gastric / Gastroesophageal Junction Cancer
Here are the drugs and financial support services available to patients receiving treatment for Gastric / Gastroesophageal Junction Cancer.
Gastric Cancer
Drugs for GIST
Here are the drugs and financial support services available to patients receiving treatment for GIST(Gastrointestestinal Stromal Tumor).
FDA Approvals, News & UpdatesNewsworthyWeb Exclusives
FDA and CDC Investigate Outbreak of Vaping-Related Illness
In the past week, the US Food and Drug Administration (FDA) has released 2 public announcements related to the use of vaping products.
FDA Approvals, News & UpdatesLymphomaNewsworthy
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Last modified: April 26, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country